Annotation Detail
Information
- Associated Genes
- FGF2
- Associated Variants
-
FGF2 EXPRESSION
FGF2 EXPRESSION - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 standard deviations. FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2. Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations. 10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1711
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1872
- Variant URL
- https://civic.genome.wustl.edu/links/variants/673
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Quizartinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 27671675
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Quizartinib | Resitance or Non-Reponse | true |